Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)
Cult stocks do well in frothy bull markets, which helps explain MannKind's inclusion on this list. The next round of pivotal clinical trials for the fast-acting inhaled insulin Afrezza are due in August, following two FDA rejections already. With MannKind shares clearly running up in anticipation of the data and the worshipping of company founder Al Mann reaching a zenith, anything less than a stellar performance from Afrezza could hit the stock hard.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts